{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"4.6"}]}],"title":"C-11 acetate PET CT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.2","value":"4.4"}]}],"title":"C-11 acetate PET MRI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"1.1"}]}],"title":"18 FDG PET CT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.8","value":"1.0"}]}],"title":"18 FDG PET MRI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The number of lesions detected in the scans will be averaged for each technique. Two techniques (scans) will be tested on Day 1 and two techniques (scans) will be tested on Day 2.","dispersionType":"Standard Deviation","groups":[{"description":"New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.\n\nFludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi).\n\nSodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).","id":"OG000","title":"Multiple Myeloma (MM) Patients"}],"paramType":"MEAN","populationDescription":"Each participant received both PET drugs by both diagnostic techniques (scans) and is therefore included in the analysis population for the four reporting groups.","reportingStatus":"POSTED","timeFrame":"Day 1, Day 2","title":"Mean Multiple Myeloma Lesions Detected","type":"PRIMARY","unitOfMeasure":"number of lesions"}